On Monday, June 24, the next meeting of the Transparency Council.
AOTMiT: Transparency Council on house dust allergy, hiercholesterolemia in children and breast cancer prevention, among others
Published June 19, 2024 09:19
Źródło: AOTMiT
The agenda includes:
1. Preparation of a position paper on the evaluation of the drug Acarizax (standardized allergenic extract of house dust mite (Dermatophagoides pteronyssinus, Dermatophagoides farina), Sublingual lyophilizate)) for the indication: treatment of adult patients (aged 18 to 65 years), whose diagnosis was made on the basis of clinical history and a positive allergic test to house dust mites (spot skin tests and / or specific immunoglobulin E) and at least one of the following conditions:
- Moderate to severe allergic rhinitis caused by house dust, persisting despite the use of medications to relieve symptoms;
- Bronchial asthma caused by house dust allergy, not controlled well with inhaled corticosteroids accompanied by moderate to severe allergic rhinitis caused by house dust.
2 Prepare an opinion on the draft health policy program of the local government unit "Program of early detection of breast cancer among residents of Olesnica for the year 2024".
3 Prepare an opinion on the draft health policy program of the local government unit "Breast cancer prevention program for women residing in the Municipality of Tczew for 2024-2025".
4. Preparation of an opinion on the continuation of the inclusion in reimbursement of medicinal products containing the active substances atorvastatinum, lovastatinum, simvastatinum in the indication: severe secondary hypercholesterolemia in children aged 10 to 18 years (with a high risk of cardiovascular complications and in the absence of effective non-pharmacological treatment) in the course of: renal failure or nephrotic syndrome, or type I diabetes mellitus (with associated microalbuminuria or renal failure), or receiving antiretroviral therapy, or following organ transplantation.
5. preparation of an opinion on the continuation of the inclusion in reimbursement of medicinal products containing the active substance propranolol in the following indications: anoxemic seizures in children under 18 years of age - prevention, early infantile hemangiomas in children under 18 years of age, flat hemangiomas, cavernous hemangiomas.
Source: AOTMiT
